Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.24)
# 2,450
Out of 4,829 analysts
46
Total ratings
43.48%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $14.45 | +45.33% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $600 → $300 | $3.34 | +8,882.04% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.71 | +739.40% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $58.97 | -38.95% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $10.68 | +368.38% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $37.59 | +325.65% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $8.60 | +365.12% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $36.09 | +190.94% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $66.58 | -59.45% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $100.31 | -0.31% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.75 | +2,757.14% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $6.15 | +4,290.24% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.32 | +12,021.21% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $14.45
Upside: +45.33%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $600 → $300
Current: $3.34
Upside: +8,882.04%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.71
Upside: +739.40%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $58.97
Upside: -38.95%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $10.68
Upside: +368.38%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $37.59
Upside: +325.65%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $8.60
Upside: +365.12%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $36.09
Upside: +190.94%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $66.58
Upside: -59.45%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $100.31
Upside: -0.31%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $1.75
Upside: +2,757.14%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $6.15
Upside: +4,290.24%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.32
Upside: +12,021.21%